SCIEX Launches the New Cornerstone of Software Ecosystem - SCIEX OS 3.0

Features include Zeno SWATH DIA, stMRM, an integrated central console and accessibility across 9 languages

At ASMS 2022, SCIEX , a global leader in life science analytical technologies, and a company of Danaher Corporation (NYSE:DHR), launches SCIEX OS software v3.0, a software ecosystem built on accessibility, connectivity and integration. With this launch, SCIEX OS software powers mass spectrometers across the SCIEX portfolio and enables the SCIEX ecosystem to deliver better quality data, boosted workflow efficiencies and comprehensive auditing advancements.

In addition to enabling Zeno SWATH DIA , also launched today, SCIEX OS software v3.0 features stMRM, a data rich, scout triggered MRM workflow . stMRM couples improved efficiency with better-quality data across vast screening workflows. It utilizes the intelligent monitoring of marker compounds to trigger the acquisition of later eluting dependent transitions to identify dependent compounds. stMRM removes analytical dependencies of chromatographic retention times allowing for improved cycle and dwell across compound transitions.

"Scout triggered MRM is being used at our institution to monitor 300 characteristic peptides in an 8 minute run-time, to specifically identify the pathogens concerned with sepsis. This research could start to impact patients in as little as 3 years," said Jérôme Lemoine from Claude Bernard Lyon 1 University.

SCIEX OS software v3.0 brings laboratory administration to a new level of efficiency and comprehension with the launch of the Central Administration Console . This new feature brings project management, user profiles, permissions and security into a simple and navigable interface.

In addition, this launch improves accessibility to SCIEX systems with new language packs. Customers will now be able to operate SCIEX OS software in 9 languages: Chinese (simplified), English, French, German, Italian, Japanese, Korean, Portuguese and Spanish.

"Globally, customers have told us they need to be connected to their data. They need it to be readily accessible. They need software, free of barriers and obstacles that will evolve as their challenges evolve, and interpret data in a way that unlocks biological meaning. Connecting people to their pursuits and the pursuits of others is the inspiration for creating this unified software ecosystem," said Joe Fox, President at SCIEX.

To learn more about SCIEX OS software v3.0, see www.sciex.com/sciexos .

About SCIEX

SCIEX delivers solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all. We have been at the forefront of the field of mass spectrometry for 50 years. From the launch of the first ever commercially successful triple quadrupole in 1981, we have developed groundbreaking technologies and solutions that influence life-changing research and outcomes.

Today, as part of the Danaher Corporation (NYSE:DHR) family of global science and technology companies, we continue to pioneer robust solutions in mass spectrometry and capillary electrophoresis. Our customers can quickly respond to environmental hazards, better understand biomarkers relevant to disease, improve patient care in the clinic, bring relevant drugs to market faster and keep food healthier and safer.

That's why thousands of life science experts around the world choose SCIEX to get the answers they can trust to better inform critical decisions that positively impact lives.

For more information, visit sciex.com .

Let's connect: Twitter , LinkedIn , Facebook , and Instagram .

Advances in human wellness depend on the power of precise science.

The SCIEX clinical diagnostic portfolio is For In Vitro Diagnostic Use. Rx Only. Product(s) not available in all countries. For information on availability, please contact your local sales representative or refer to www.sciex.com/diagnostics . All other products are For Research Use Only. Not for use in Diagnostic Procedures.

Trademarks and/or registered trademarks mentioned herein, including associated logos, are the property of AB Sciex Pte. Ltd. or their respective owners in the United States and/or certain other countries (see www.sciex.com/trademarks ).

© 2022 DH Tech. Dev. Pte. Ltd. RUO-MKT-12-14840-A.

Lulu VanZandt
Senior Manager, Brand, Public Relations and Social Media
lulu.vanzandt@sciex.com
M: +1 (508) 782-9484

News Provided by Business Wire via QuoteMedia

DHR
The Conversation (0)
Discovery Harbour Approved All Resolutions at Annual and Special Meeting

Discovery Harbour Approved All Resolutions at Annual and Special Meeting

Discovery Harbour Resources Corp. (TSXV: DHR) (OTC Pink: DCHRF) (FSE: 4GW) (the "Company" or "Discovery Harbour") shareholders approved all resolutions at the Company's annual and special meeting which was held on May 5, 2023. Details of these matters are disclosed in the management information... Keep Reading...
ALDEVRON ANNOUNCES EXPANSION OF mRNA PRODUCTION CAPABILITY

ALDEVRON ANNOUNCES EXPANSION OF mRNA PRODUCTION CAPABILITY

Will offer mRNA cGMP Production from Master Cell Bank to Drug Product Made Possible with Precision Nanosystems and Cytiva Aldevron, a leading global manufacturer of DNA, RNA and proteins used in cell and gene therapies and vaccine development, will expand its mRNA production capabilities to... Keep Reading...

Danaher Reports First Quarter 2023 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2023. Net earnings refer to net earnings attributable to common shareholders. For the quarter ended March 31, 2023 net earnings were $1.4 billion , or $1.94 per diluted common share and non-GAAP... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at... Keep Reading...
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or... Keep Reading...
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the... Keep Reading...
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries CommenceDownload the PDF here. Keep Reading...

Latest Press Releases

Related News